Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
Titel:
Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
Auteur:
Kennedy, Oliver J. Kicinski, Michal Valpione, Sara Gandini, Sara Suciu, Stefan Blank, Christian U. Long, Georgina V. Atkinson, Victoria G. Dalle, Stéphane Haydon, Andrew M. Meshcheryakov, Andrey Khattak, Adnan Carlino, Matteo S. Sandhu, Shahneen Larkin, James Puig, Susana Ascierto, Paolo A. Rutkowski, Piotr Schadendorf, Dirk Koornstra, Rutger Hernandez-Aya, Leonel Di Giacomo, Anna M. van den Eertwegh, Alfonsus J.M. Grob, Jean-Jacques Gutzmer, Ralf Jamal, Rahima van Akkooi, Alexander C.J. Robert, Caroline Eggermont, Alexander M.M. Lorigan, Paul Mandala, Mario